Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
NEW YORK, Feb. 09, 2016 -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Dr. Jason Slakter, Chief Executive Officer, will present a corporate overview and business update at the Leerink Global Healthcare Conference at the Waldorf Astoria in New York, NY.
Details of the Presentations:
Date: Thursday, February 11
Time: 10:45am Eastern
Room: Carnegie Suite
Webcast: http://wsw.com/webcast/leerink26/ohrp
About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) is an ophthalmology research and development company. The company's lead product, OHR-102 (Squalamine Lactate Ophthalmic Solution, 0.2%), is currently being studied as an eye drop formulation in clinical trials for back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. Additional information on the company may be found at www.ohrpharmaceutical.com.
Contact: Ohr Pharmaceutical Inc. Investor Relations 888-388-2327 [email protected] LifeSci Advisors, LLC Michael Wood 646-597-6983 [email protected]
